NCT06124677Completed
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
Anatomical and Visual Outcomes Following a Single Injection of Intravitreal Faricimab in Patients With Neovascular Age-related Macular Degeneration and Persisting Fluid Despite Frequent Aflibercept Treatments
Source: ClinicalTrials.gov · Last updated 11 Dec 2023
Brief summary (registry, in English)
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 46 (actual)
- First submitted
- 1 Nov 2023
- Start date
- 1 Nov 2023
- Primary completion date
- 15 Nov 2023
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Macular degeneration
- NCT number
- NCT06124677
What you commit to
- Study type: Observational
- Participants enrolled: 46
- From 1 Nov 2023 to the primary completion date, 15 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch
Other illness
- Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
Other
- Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
Who the study is looking for
- Presence of neovascular age-related macular degeneration (AMD) in the study eye
- \>50 years of age
- Previous intravitreal anti-VEGF treatment with aflibercept (Eylea®) or with aflibercept and ranibizumab (Lucentis®) in the study eye
- Minimum of 6 monthly aflibercept injections
- Persisting intraretinal or subretinal fluid or both, despite at least 3 consecutive monthly aflibercept injections in the study eye before switching to faricimab
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Miklos Schneider Coordinator of this site? Confirm its status | Glostrup Municipality | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.